Login to Your Account

Gilead's banner HCV sales ramp upward

By Michael Fitzhugh
Staff Writer

Tuesday, February 3, 2015

Sales of Gilead Sciences Inc.'s top HCV drugs continued to boom in the fourth quarter amid new competition, totaling about $3.8 billion, and helping lead the company to a profit more than four times higher than the same quarter last year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription